<DOC>
	<DOCNO>NCT00656006</DOCNO>
	<brief_summary>A Study Albuferon Ribavirin Interferon Alfa Naive Subjects Chronic Hepatitis C Genotype 2 3 .</brief_summary>
	<brief_title>A Study Albuferon With Ribavirin Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 3</brief_title>
	<detailed_description>A Randomized , Multi-Center , Open-Label Study To Evaluate The Efficacy And Safety Of Albuferon ( HGS 1008 , Recombinant Human Albumin-Interferon Alfa Fusion Protein ) In Combination With Ribavirin In Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 OR 3</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Have clinical diagnosis chronic hepatitis C basis detectable serum HCV RNA screen period least 6month history exposure risk factor HCV . Have never receive treatment interferon alfa product interferon alfa combination product . Have HCV genotype 2 3 . Have compensate liver disease follow minimum criterion : white blood cell count ( WBC ) &gt; 3,000/mm3 , absolute neutrophil count ( ANC ) &gt; 1,800/mm3 , platelet &gt; 100,000/mm3 , hemoglobin ( Hb ) &gt; 13 g/dL male &gt; 12 g/dL female . Evidence decompensated liver disease . Pregnant lactate female . History medical disease condition would make subject ( opinion investigator ) unsuitable study . A current drug alcohol addiction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Chronic</keyword>
	<keyword>Genotype 2 3</keyword>
	<keyword>Treatment naive</keyword>
</DOC>